< Back to Active Studies
Anti-TAU Vaccine (AV-1980R) Study for Preclinical Alzheimer’s Disease
Who May Qualify?
You must be:
An individual between the ages of 65-80 years old who may be at an increased risk for Alzheimer’s Disease, but are currently without significant memory impairment.
Why Should I Participate?
Proactive Prevention: TAU Protein buildup is a primary hallmark of Alzheimer’s. Early Active vaccination aims to prevent this accumlation.
Slow Cognitive Decline: Helping protect brain health and memory functions early.
Evaluate Safety: Help researchers determine the safety and tolerability of this novel investigational vaccine.
What is the purpose of this study?
To evaluate the safety and tolerability of an investigational anti-TAU vaccine (AV-1980R) designed to prevent or delay Alzheimer’s Disease before symptoms begin.
How long will the study last?
Your participation in this study will be 58 weeks, including in-person visits and diagnostic imaging. Participants will receive three intramuscular injections at Weeks 0, 4, and 38, with follow-up visits through Week 58.
What is a clinical research study?
It is voluntary participation in a study conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, devices, other therapies, or new ways of using existing treatments. As outlined above, our device has no known health risks.
For additional study information, please contact: